集成干扰素α(辉阳生命)(rSIFN-co) - 药物靶点：IFNLR1_在研适应症：慢性乙型肝炎，实体瘤_专利_临床

概要

基本信息

药物类型

干扰素

别名

Crystalline recombinant interferon、Recombinant super compound interferon、Recombinant super interferon compound

+ [1]

靶点

IFNLR1

作用机制

IFNLR1激动剂(干扰素λ受体1激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 8226

关联

4

项与集成干扰素α(辉阳生命) 相关的临床试验

NCT05485584 / Active, not recruiting临床2期

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19

This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.

开始日期2022-07-01

申办/合作机构

四川辉阳生命工程股份有限公司

NCT02464007 / Active, not recruiting临床1期

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

In this EffTox dose escalation study, up to 3 dose levels will be tested. The optimal dose (OD) of rSIFN-co will be determined using the EffTox design. Additional subject cohorts will not be enrolled until all subjects at the current dose level complete 28 days without DLT. The optimal dose (OD) will be determined by evaluation of safety in each cohort and disease response by RECIST 1.1 at 8 weeks. Once the OD is determined, enrollment will continue until at least 9 subjects total are accrued at the OD. Pharmacokinetics of rSIFN-co will be conducted for all tested dose levels to characterize dose proportionality.

开始日期2016-01-01

申办/合作机构

四川辉阳生命工程股份有限公司

[+1]

NCT02387307 / Completed临床1期

A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer

This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).

开始日期2013-07-01

申办/合作机构

四川辉阳生命工程股份有限公司

100 项与集成干扰素α(辉阳生命) 相关的临床结果

登录后查看更多信息

100 项与集成干扰素α(辉阳生命) 相关的转化医学

登录后查看更多信息

100 项与集成干扰素α(辉阳生命) 相关的专利（医药）

登录后查看更多信息

217

项与集成干扰素α(辉阳生命) 相关的文献（医药）

2024-09-01·Brazilian Journal of Otorhinolaryngology

Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection

Article

作者: Anastasia, Kozlova ; Andrey, Boyko ; Pavel, Tregub ; Vladimir, Petrovskii ; Irada, Ibrahimli ; Inga, Popova ; Timur, Shadyev ; Irina, Apollonova ; Svetlana, Starostina ; Tatiana, Degtyarevskaya

OBJECTIVESExophytic Sinonasal Papilloma (ESP) is a benign tumor of the sinonasal tract. Complete surgical excision by endoscopic surgery is the treatment of choice. However, a high recurrence rate (36% at 5-year follow-up) is associated with this method, which may indicate the presence of microorganisms such as Human Papillomavirus (HPV). It is important to note that the standard treatment for ESP does not include antiviral drugs. In our study, we are testing the effectiveness of an interferon-containing drug in reducing recurrence and postoperative reactions in patients with ESP.METHODSWe included 78 patients aged 23-83 years with a confirmed diagnosis of ESP by rhinoscopy and nasal endoscopy and a positive PCR test for HPV in nasal scrapings. To compare the results, we divided the patients into main and control groups. The main group received recombinant human interferon after surgery, while the control group did not receive the drug. We performed a statistical analysis to compare the proportion of patients without reactive manifestations at different stages of the postoperative period, as well as to compare the proportion of patients with recurrent ESP at certain stages of observation.RESULTSThe introduction of recombinant human interferon accelerated the resolution of postoperative reactions and promoted the healing of the nasal mucosa after surgical removal of the ESP. We also found a statistically significant association between treatment with recombinant interferon and a reduction in the recurrence rate of ESP.CONCLUSIONAccording to the results of the study, it was found that in the main group of patients who received rhIFN-α2b (recombinant human Interferon alpha 2b) in the postoperative period, the frequency of relapses of ESP and the time of postoperative recovery were significantly lower than in patients in the control group who did not take the drug.LEVEL OF EVIDENCECohort Study.

2023-07-01·Antiviral Research

Recombinant porcine interferon cocktail delays the onset and lessens the severity of African swine fever

Article

作者: Fan, Wenhui ; Yin, Hongyan ; Zhang, He ; Shang, Yingli ; Jiao, Pengtao ; Wang, Shuchao ; Sun, Lei ; Liu, Wenjun ; Zhu, Hongfei ; Hu, Rongliang

African swine fever (ASF) is a highly contagious and deadly disease that affects domestic and wild pigs. No commercial vaccine or antiviral is currently available against ASF. The control of ASF primarily relies on implementing effective biosecurity measures during the breeding process. Here, we evaluated the preventive and therapeutic potential of the interferon (IFN) cocktail (a mixture of recombinant porcine IFN α and γ) on ASF. The IFN cocktail treatment delayed the onset of ASF symptoms and ASF virus (ASFV) replication for approximately one week. However, IFN cocktail treatment could not prevent the death of the pigs. Further analysis showed that IFN cocktail treatment increased the expression of multiple IFN-stimulated genes (ISGs) in porcine peripheral blood mononuclear cells in vivo and in vitro. Additionally, IFN cocktail modulated the expression of pro- and anti-inflammatory cytokines and reduced tissue injury in the ASFV-infected pigs. Collectively, the results suggest that the IFN cocktail restricts the progression of acute ASF by inducing high levels of ISGs, contributing to the pre-establishment of antiviral status, and modulating the balance of pro- and anti-inflammatory mediators to lessen cytokine storm-mediated tissue damage.

2022-10-15·Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

上海380例家庭聚集性感染Omicron变异株的儿童及其家属临床特征分析.

Article

作者: Li, Miao-Chen ; Jiang, Qin ; Chen, Juan-Juan ; Zhang, Kun ; Guo, Zhi ; Zhang, Jin-Ping ; Fan, Sai-Nan ; Guo, Miao-Miao ; Zheng, Fang ; Wu, Zhi-Min ; Hui, Lei ; Bian, Xiang-Li

目的: 分析亲子病房收治模式下，家庭聚集性感染Omicron变异株的儿童及其家属的临床特点及转归。方法: 回顾性收集上海市第六人民医院新型冠状病毒肺炎（coronavirus disease 2019，COVID-19）定点医院于2022年4月8日至5月10日收治确诊的感染Omicron变异株患儿190例及其家属190例的临床资料，进行分析总结。结果: 儿童组和成人组均以轻型为主，儿童组轻型比例高于成人组（P<0.05）；2组临床表现均以上呼吸道症状为主，儿童组发热、腹痛腹泻、喘息发生率高于成人组（P<0.05），鼻塞流涕咳嗽、咽干咽痒咽痛发生率低于成人组（P<0.05）；成人组治疗连花清瘟颗粒/小儿豉翘清热颗粒、中药汤剂、重组人干扰素α2b喷雾剂、止咳化痰药、奈玛特韦/利托那韦片使用率均高于儿童组（P<0.05）；儿童组疫苗接种率（30.5%）较成人组（71.1%）低（P<0.001），而儿童组严重急性呼吸综合征冠状病毒2（severe acute respiratory syndrome coronavirus 2，SARS-CoV-2）核酸阳性持续时间短于成人组（P<0.05）。2组临床轻型者SARS-CoV-2核酸阳性持续时间短于普通型者（P<0.05）。2组有基础疾病者SARS-CoV-2核酸阳性持续时间长于无基础疾病者（P<0.05）。结论: 家庭聚集性Omicron变异株感染儿童和成人的临床分型均以轻型为主。尽管儿童疫苗接种率较低，但在亲子病房收治模式中，疾病恢复较快，SARS-CoV-2核酸阳性持续时间短于成人。.

100 项与集成干扰素α(辉阳生命) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15752

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性乙型肝炎	临床3期	中国	四川辉阳生命工程股份有限公司	2011-09-17
实体瘤	临床1期	美国	四川辉阳生命工程股份有限公司	2016-01-01
晚期恶性实体瘤	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01
结肠癌	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01
肝细胞癌	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01
黑色素瘤	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01
非小细胞肺癌	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01
肾细胞癌	药物发现	新加坡	四川辉阳生命工程股份有限公司	2013-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02387307 (ESMO2019)	临床1期	HR阳性/HER2低表达实体瘤	39	rSIFN-co	(網構鹽齋鬱膚憲廠蓋繭) = 鬱憲廠襯鹹網簾獵範鹹簾製選構膚餘醖網窪選 (獵觸網鹹廠獵夢鑰鏇網 )	-	2019-09-28